301 related articles for article (PubMed ID: 25492085)
1. MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung.
Schildhaus HU; Schultheis AM; Rüschoff J; Binot E; Merkelbach-Bruse S; Fassunke J; Schulte W; Ko YD; Schlesinger A; Bos M; Gardizi M; Engel-Riedel W; Brockmann M; Serke M; Gerigk U; Hekmat K; Frank KF; Reiser M; Schulz H; Krüger S; Stoelben E; Zander T; Wolf J; Buettner R
Clin Cancer Res; 2015 Feb; 21(4):907-15. PubMed ID: 25492085
[TBL] [Abstract][Full Text] [Related]
2. High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer.
Go H; Jeon YK; Park HJ; Sung SW; Seo JW; Chung DH
J Thorac Oncol; 2010 Mar; 5(3):305-13. PubMed ID: 20107422
[TBL] [Abstract][Full Text] [Related]
3. Alterations of MET Gene Copy Number and Protein Expression in Primary Non-Small-Cell Lung Cancer and Corresponding Nodal Metastases.
Tran TN; Selinger CI; Kohonen-Corish MR; McCaughan B; Kennedy C; O'Toole SA; Cooper WA
Clin Lung Cancer; 2016 Jan; 17(1):30-8.e1. PubMed ID: 26395411
[TBL] [Abstract][Full Text] [Related]
4. Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients.
Tanaka A; Sueoka-Aragane N; Nakamura T; Takeda Y; Mitsuoka M; Yamasaki F; Hayashi S; Sueoka E; Kimura S
Lung Cancer; 2012 Jan; 75(1):89-94. PubMed ID: 21733594
[TBL] [Abstract][Full Text] [Related]
5. MET amplification, protein expression, and mutations in pulmonary adenocarcinoma.
Park S; Koh J; Kim DW; Kim M; Keam B; Kim TM; Jeon YK; Chung DH; Heo DS
Lung Cancer; 2015 Dec; 90(3):381-7. PubMed ID: 26791796
[TBL] [Abstract][Full Text] [Related]
6. CRKL amplification is rare as a mechanism for acquired resistance to kinase inhibitors in lung cancers with epidermal growth factor receptor mutation.
Suda K; Mizuuchi H; Murakami I; Uramoto H; Tanaka F; Sato K; Takemoto T; Iwasaki T; Sekido Y; Yatabe Y; Mitsudomi T
Lung Cancer; 2014 Aug; 85(2):147-51. PubMed ID: 24939008
[TBL] [Abstract][Full Text] [Related]
7. Amplification and overexpression of CMET is a common event in brain metastases of non-small cell lung cancer.
Preusser M; Streubel B; Berghoff AS; Hainfellner JA; von Deimling A; Widhalm G; Dieckmann K; Wöhrer A; Hackl M; Zielinski C; Birner P
Histopathology; 2014 Nov; 65(5):684-92. PubMed ID: 25039982
[TBL] [Abstract][Full Text] [Related]
8. MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis.
Tong JH; Yeung SF; Chan AW; Chung LY; Chau SL; Lung RW; Tong CY; Chow C; Tin EK; Yu YH; Li H; Pan Y; Chak WP; Ng CS; Mok TS; To KF
Clin Cancer Res; 2016 Jun; 22(12):3048-56. PubMed ID: 26847053
[TBL] [Abstract][Full Text] [Related]
9. Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.
Saigi M; McLeer-Florin A; Pros E; Nadal E; Brambilla E; Sanchez-Cespedes M
Clin Transl Oncol; 2018 Jul; 20(7):881-888. PubMed ID: 29139039
[TBL] [Abstract][Full Text] [Related]
10. Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement.
Schwab R; Petak I; Kollar M; Pinter F; Varkondi E; Kohanka A; Barti-Juhasz H; Schönleber J; Brauswetter D; Kopper L; Urban L
Lung Cancer; 2014 Jan; 83(1):109-11. PubMed ID: 24192513
[TBL] [Abstract][Full Text] [Related]
11. Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer.
Schildhaus HU; Heukamp LC; Merkelbach-Bruse S; Riesner K; Schmitz K; Binot E; Paggen E; Albus K; Schulte W; Ko YD; Schlesinger A; Ansén S; Engel-Riedel W; Brockmann M; Serke M; Gerigk U; Huss S; Göke F; Perner S; Hekmat K; Frank KF; Reiser M; Schnell R; Bos M; Mattonet C; Sos M; Stoelben E; Wolf J; Zander T; Buettner R
Mod Pathol; 2012 Nov; 25(11):1473-80. PubMed ID: 22684217
[TBL] [Abstract][Full Text] [Related]
12. Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer.
Dziadziuszko R; Wynes MW; Singh S; Asuncion BR; Ranger-Moore J; Konopa K; Rzyman W; Szostakiewicz B; Jassem J; Hirsch FR
J Thorac Oncol; 2012 Feb; 7(2):340-7. PubMed ID: 22237262
[TBL] [Abstract][Full Text] [Related]
13. High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer.
Preusser M; Berghoff AS; Berger W; Ilhan-Mutlu A; Dinhof C; Widhalm G; Dieckmann K; Wöhrer A; Hackl M; von Deimling A; Streubel B; Birner P
Lung Cancer; 2014 Jan; 83(1):83-9. PubMed ID: 24183471
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.
Hirsch FR; Varella-Garcia M; Bunn PA; Di Maria MV; Veve R; Bremmes RM; Barón AE; Zeng C; Franklin WA
J Clin Oncol; 2003 Oct; 21(20):3798-807. PubMed ID: 12953099
[TBL] [Abstract][Full Text] [Related]
15. Tumor-suppressive microRNA-206 as a dual inhibitor of MET and EGFR oncogenic signaling in lung squamous cell carcinoma.
Mataki H; Seki N; Chiyomaru T; Enokida H; Goto Y; Kumamoto T; Machida K; Mizuno K; Nakagawa M; Inoue H
Int J Oncol; 2015 Mar; 46(3):1039-50. PubMed ID: 25522678
[TBL] [Abstract][Full Text] [Related]
16. Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis.
Noonan SA; Berry L; Lu X; Gao D; Barón AE; Chesnut P; Sheren J; Aisner DL; Merrick D; Doebele RC; Varella-Garcia M; Camidge DR
J Thorac Oncol; 2016 Aug; 11(8):1293-1304. PubMed ID: 27262212
[TBL] [Abstract][Full Text] [Related]
17. EGFR gene copy number increase in vulvar carcinomas is linked with poor clinical outcome.
Woelber L; Hess S; Bohlken H; Tennstedt P; Eulenburg C; Simon R; Gieseking F; Jaenicke F; Mahner S; Choschzick M
J Clin Pathol; 2012 Feb; 65(2):133-9. PubMed ID: 22128196
[TBL] [Abstract][Full Text] [Related]
18. SOX2 amplification is a common event in squamous cell carcinomas of different organ sites.
Maier S; Wilbertz T; Braun M; Scheble V; Reischl M; Mikut R; Menon R; Nikolov P; Petersen K; Beschorner C; Moch H; Kakies C; Protzel C; Bauer J; Soltermann A; Fend F; Staebler A; Lengerke C; Perner S
Hum Pathol; 2011 Aug; 42(8):1078-88. PubMed ID: 21334718
[TBL] [Abstract][Full Text] [Related]
19. Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma.
Dacic S; Flanagan M; Cieply K; Ramalingam S; Luketich J; Belani C; Yousem SA
Am J Clin Pathol; 2006 Jun; 125(6):860-5. PubMed ID: 16690485
[TBL] [Abstract][Full Text] [Related]
20. MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium.
Guo R; Berry LD; Aisner DL; Sheren J; Boyle T; Bunn PA; Johnson BE; Kwiatkowski DJ; Drilon A; Sholl LM; Kris MG
J Thorac Oncol; 2019 Sep; 14(9):1666-1671. PubMed ID: 31228623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
